J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
First published on June 4, 2008, doi:10.1177/0091270008319329

The Journal of Clinical Pharmacology 2008;48:849.

This Article
Right arrow Full Text (JCP OnlineFirst[PDF])
Right arrow All Versions of this Article:
0091270008319329v1
48/7/849    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, J. A.
Right arrow Articles by Wrighton, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, J. A.
Right arrow Articles by Wrighton, S. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
©© 2008 American College of Clinical Pharmacology, Inc.
The Journal of Clinical Pharmacology , 10.1177/0091270008319329

Article

PhRMA White Paper on ADME Pharmacogenomics

J. Andrew Williams 1, Tommy Andersson 2, Tommy B. Andersson 2, Rebecca Blanchard 3, Martin Otto Behm 3, Nadine Cohen 4, Timi Edeki 2, Monique Franc 4, Kathleen M. Hillgren 5, Keith J. Johnson 1, David A. Katz 6, Mark N. Milton 7, Bernard P. Murray 8, Joseph W. Polli 9, Deb Ricci 4, Lisa A. Shipley 5, Subrahmanyam Vangala 10, and Steven A. Wrighton 5

1 Pfizer
2 AstraZeneca
3 Merck
4 Johnson & Johnson
5 Eli Lilly
6 Abbott
7 Tempo
8 Gilead
9 GlaxoSmithKline
10 Sai Advantium Pharma Limited


  Abstract
Pharmacogenomic (PGx) research on the absorption, distribution, metabolism, and excretion (ADME) properties of drugs has begun to have impact for both drug development and utilization. To provide a cross-industry perspective on the utility of ADME PGx, the Pharmaceutical Research and Manufacturers of America (PhRMA) conducted a survey of major pharmaceutical companies on their PGx practices and applications during 2003-2005. This white paper summarizes and interprets the results of the survey, highlights the contributions and applications of PGx by industrial scientists as reflected by original research publications, and discusses changes in drug labels that improve drug utilization by inclusion of PGx information. In addition, the paper includes a brief review on the clinically relevant genetic variants of drug-metabolizing enzymes and transporters most relevant to the pharmaceutical industry.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American College of Clinical Pharmacology